RELIEF: The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

View Activity

PROGRAM CHAIR

Leonard Calabrese, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
RJ Fasenmyer Chair of Immunology Department of Rheumatic
and Immunologic Disease Cleveland Clinic
Cleveland, OH

FACULTY

Elaine Tozman, MD
Associate Professor of Clinical
University of Miami
Miami, FL

PROGRAM OVERVIEW

This enduring activity is primarily designed for U.S.-based members of multidisciplinary teams involved in the management of patients with Axial Spondyloarthritis (AxSpA).

TARGET AUDIENCE

This activity is designed for U.S.-based academic and community-based rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of AxSpA and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with axial spondyloarthritis.
CNE Credits: 1.0 ANCC Contact Hour.

DISCLOSURE POLICY STATEMENT

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY

Dr. Leonard Calabrese reports that he has served on speaker’s bureau and as a consultant for Novartis, AbbVie, Jansen, Genentech, Lilly, and Horizon. In addition, he has served as a consultant for Pfizer and Gilead.

Dr. Elaine Tozman reports that she has no relevant relationships with a commercial entity or manufacturer.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.

Chris Drury, Medical and Scientific Services for Med Learning Group has nothing to disclose.

Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.

Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group has nothing

Sharine Griggs, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete pre-and-post survey.
4. Submit the evaluation form online.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: April 13, 2020

EXPIRATION DATE: April 13, 2021

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.